Macugen

RSS

pegaptanib

Withdrawn
This medicine is now withdrawn from use in the European Union.

Overview

The marketing authorisation for Macugen has been withdrawn at the request of the marketing-authorisation holder.

This EPAR was last updated on 27/06/2019

Authorisation details

Product details
Name
Macugen
Agency product number
EMEA/H/C/000620
Active substance
pegaptanib
International non-proprietary name (INN) or common name
pegaptanib
Therapeutic area (MeSH)
Wet Macular Degeneration
Anatomical therapeutic chemical (ATC) code
S01LA03
Publication details
Marketing-authorisation holder
PharmaSwiss Ceska Republika s.r.o
Revision
15
Date of issue of marketing authorisation valid throughout the European Union
31/01/2006
Contact address
Jankovcova 1569/2c
Lighthouse
17000 Prague 7
Czech Republic

Product information

20/07/2016 Macugen - EMEA/H/C/000620 - IB/0065

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Ophthalmologicals

Therapeutic indication

Macugen is indicated for the treatment of neovascular (wet) age-related macular degeneration (AMD).

Assessment history

How useful was this page?

Add your rating